The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1381
January 9, 2012
View Complete Issue         Table of Contents 2019 
Vandetanib (Caprelsa) for Medullary Thyroid Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Vandetanib (Caprelsa) for Medullary Thyroid Cancer
January 9, 2012 (Issue: 1381)
The FDA recently approved vandetanib [van det´ a nib] (Caprelsa – AstraZeneca) for oral treatment of symptomatic or progressive medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Vandetanib is...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Vandetanib (Caprelsa) for Medullary Thyroid Cancer
Article code: 1381b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.